From: Update on microbicide research and development-seeking new HIV prevention tools for women
Trial Name (Number) | Phase | Description | Location | Sponsor | No. of Subjects | Population | Intervention(s) | Results Expected |
---|---|---|---|---|---|---|---|---|
FEM-PrEP | III | Safety & effectiveness | Kenya, South Africa, Tanzania, Zimbabwe | FHI, USAID, BMGF | 3900 | Heterosexual women | Daily oral TDF/FTC | Q3 2013 |
iPrEs | III | Safety & effectiveness | Brazil, Ecuador, Peru, South Africa, Thailand, US | NIH, BMGF | 2499 | Men who have sex with men | Daily oral TDF/FTC | Q4 2010 [39] |
Partners PrEP | III | Safety & effectiveness | Kenya, Uganda | BMGF | 4700 | Serodiscordant heterosexual couples | Daily oral TDF; daily oral TDF/FTC | Ql 2013 |
Bangkok Tenofovir Study (CDC 4370) | II/III | Safety & effectiveness | Thailand | CDC | 2400 | Injection drug users | Daily oral TDF | Ql 2012 |
VOICE (MTN 003) | IIB | Safety & effectiveness | South Africa, Uganda, Zimbabwe | MTN, NIH | 5000 | Heterosexual women | Daily oral TDF; daily oral TDF/FTC; daily topical tenofovir gel | Ql 2013 |
PrEP in YMSM (ATN 082) | II | Safety, acceptability, & feasibility | US | ATN, NICHD | 99 | Young men who have sex with men | Daily oral TDF/FTC | Q2 2011 |
TDF2 (CDC 4940) | II | Safety & adherence | Botswana | CDC | 1200 | Heterosexual men and women | Daily oral TDF/FTC | Q2 2011 |
IAVI E001 & E002 | I/II | Safety, acceptability, & adherence | Kenya, Uganda | IAVI | 150 | Serodiscordant couples and men and women | Daily oral TDF/FTC; intermittent oral TDF/FTC (twice weekly + coital dosing) | Q4 2010 |
TMC278-TiDP15-C158* | I | Safety, tolerance & pharmaco-kinetics | UK | Tibotec Pharmaceucals | 100 | Men and women | TMC278LA injected IM | Ql 2011 |